share_log

Canaccord Genuity Downgrades Galmed Pharmaceuticals to Hold, Lowers Price Target to $1

Canaccord Genuity Downgrades Galmed Pharmaceuticals to Hold, Lowers Price Target to $1

Canaccord Genuity 將高美藥業的評級下調至持有,將目標股價下調至1美元
Benzinga Real-time News ·  2022/08/08 06:14

Canaccord Genuity analyst Edward Nash downgrades Galmed Pharmaceuticals (NASDAQ:GLMD) from Buy to Hold and lowers the price target from $5 to $1.

Cancord Genuity分析師愛德華·納什將加萊德製藥(納斯達克:GLMD)的評級從買入下調至持有,並將目標價從5美元下調至1美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論